Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nab-paclitaxel + capecitabine first-line treatment for HER2-negative metastatic breast cancer
ChiCTR-ONC-14004365Phase 2Recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Apr 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nab-paclitaxel and capecitabine in breast cancer, sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Progression-free survival. Started Apr 2014; status: recruiting.
02
Drugs
nab-paclitaxelcapecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR-ONC-14004365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-ONC-14004365.